Margaret AWinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor
To the Editor: In his commentary on epidemiologic
studies and meta-analysis in drug development and surveillance, Dr Temple1 suggests that medical journals impose 3 higher
standards on epidemiologic studies. Two of these should invoke little concern.
Who is not in favor of any scientist doing a better job describing methods
and their limitations? However, Temple's third suggestion—that epidemiologic
studies with relative risks of 2.0 or less not be published until replicated
in a different environment—is alarming.
Weed DL. Higher Standards for Epidemiologic Studies—Replication Prior to Publication?. JAMA. 1999;282(10):937-938. doi:10.1001/jama.282.10.937